Country: Canada
Language: English
Source: Health Canada
OFLOXACIN
SANDOZ CANADA INCORPORATED
S01AE01
OFLOXACIN
0.3%
SOLUTION
OFLOXACIN 0.3%
OPHTHALMIC
5ML
Prescription
ANTIBACTERIALS
Active ingredient group (AIG) number: 0122759007; AHFS:
CANCELLED POST MARKET
2019-08-01
_ _ _Sandoz Ofloxacin _ _Page 1 of 26_ PRODUCT MONOGRAPH PR SANDOZ OFLOXACIN (Ofloxacin Ophthalmic Solution USP, 0.3%) Antibacterial Agent Sandoz Canada Inc. 145, Jules-Léger Boucherville, QC J4B 7K8 Date of Revision: May 9, 2018 Submission Control No: 215604 _ _ _Sandoz Ofloxacin _ _Page 2 of 26_ PR SANDOZ OFLOXACIN (Ofloxacin Ophthalmic Solution USP, 0.3%) THERAPEUTIC CLASSIFICATION Antibacterial Agent ACTION AND CLINICAL PHARMACOLOGY The primary mechanism of action of ofloxacin appears to be the specific inhibition of DNA gyrase (topoisomerase II). This enzyme is responsible for the negative supercoiling of bacterial DNA and consequently for its topological configuration, governing functions such as RNA transcription, protein synthesis, DNA replication and repair functions. INDICATIONS AND CLINICAL USE Sandoz Ofloxacin (Ofloxacin Ophthalmic Solution USP, 0.3%) is indicated for the treatment of conjunctivitis when caused by susceptible strains of the following bacteria: GRAM POSITIVE BACTERIA _Staphylococcus aureus _ _Staphylococcus epidermidis _ _Streptococcus pneumoniae _ _ _ GRAM NEGATIVE BACTERIA _Haemophilus influenza _ To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ofloxacin Ophthalmic Solution 0.3% and other antibacterial drugs, Ofloxacin Ophthalmic Solution 0.3% should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. CONTRAINDICATIONS Ofloxacin Ophthalmic Solution 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin or to any of the components of this medication. A history of hypersensitivity to other quinolones also contraindicates use of ofloxacin. WARNING _ _ _Sandoz Ofloxacin _ _Page 3 of 26_ Ofloxacin Ophthalmic Solution 0.3% is not for injection into the eye. In patients receiving systemic quinolone therapy, serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported. Some reactions were accompanied by cardiovascular Read the complete document